Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease

International Journal of Geriatric Psychiatry

Volumn 19, Issue 1, 2004, Pages 1-8

  Leroi, Iracema ^a   Brandt, Jason ^b   Reich, Stephen G ^b   Lyketsos, Constantine G ^b   Grill, Stephen ^b   Thompson, Richard ^c   Marsh, Laura ^b  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cholinesterase inhibitors; Cognitive impairment; Dementia; Donepezil; Neuropsychiatry; Parkinson's disease

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO;

ADULT; AGED; ARTICLE; ATTENTION; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPTH PERCEPTION; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GAIT DISORDER; HALLUCINATION; HUMAN; HYPERSALIVATION; MALE; MEMORY; MOTOR PERFORMANCE; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; PARKINSON DISEASE; PARKINSONISM; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINORRHEA; SIDE EFFECT; URINARY FREQUENCY; VOMITING;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DEMENTIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PARKINSON DISEASE; PILOT PROJECTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 0842325101     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.993     Document Type: Article

References (47)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. 2001. Risk of dementia in Parkinson's disease. A community-based prospective study. Neurology 56: 730-736.
2. Aarsland D, Laake K, Larsen JP, Janvin C. 2002. Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study. J Neurol Neurosurg Psychiatry 72: 708-712.
3. Aarsland D, Larsen JP, Cummings JL, Laake K. 1999. Prevalence and clinical correlates of psychotic symptoms in Parkinson Disease. A community-based study. Arch Neurol 56: 595-601.
4. Aarsland D, Larsen JP, Karlsen K, et al. 1999. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14: 866-874.
5. Albert ML, Feldman RG, Willis AL. 1974. The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37: 121-130.
6. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. 1988. Cornell Scale for Depression in Dementia. Biol Psychiatry 23: 271-284.
7. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Press: Washington, DC.
8. Barr A, Brandt J. 1996. Word-list generation deficits in dementia. J Clin Exp Neuropsychol 18: 810-822.
9. Beery KE. 1989. Revised Administration, Scoring and Teaching Manual for the Development Test of Visual-Motor Integration. Modern Curriculum Press: Cleveland.
10. Blair JR, Spreen O. 1989. Predicting premorbid IQ: A revision of the National Adult Reading Test. Clin Neuropsychol 3: 129-136.
11. Braak H, Braak E. 1990. Cognitive impairment in Parkinson's disease: Amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J Neural Transm [PD-Sect] 2: 45-57.
12. Brandt J, Benedict RHB. 2001. Hopkins Verbal Learning Test-Revised, Professional Manual. Psychological Assessment Resources Inc.: Odessa, FL.
13. Cummings JL. 1997. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48: 10-16.
14. Cummings JL. 2000. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 157: 4-15.
15. Dubois B, Pillon B. 1997. Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8.
16. Dubois B, Pillon B. 1999. Dementia in Parkinson's disease. In Mental Dysfunction in Parkinson's Disease II, Wolters EC, Sheltens PH, Berendse HW (eds). Academic Pharmaceutical Productions: Utrecht; 165-176.
17. Duvoisin RC. 1967. Cholinergic-anticholinergic antagonism in Parkinsonism. Arch Neurol 7: 124-136.
18. Fahn S, Elton RL, Members of the UPDRS Development Committee. 1987. Unified Parkinson's disease rating scale. In Recent Developments in Parkinson's Disease II, Fahn S, Marsden CD, Goldstein M (eds). Macmillan: New York; 153-163.
19. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
20. Hietanen M, Teravainen H. 1989. The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 52: 1221-1227.
21. Hoehn MM, Yahr MD. 1967. Parkinsonism: Onset, progression, and mortality. Neurology 17: 427-442.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
23. Hughes TA, Ross H, Mindham R, Spokes E. 1999. The Leeds study of dementia in Parkinson's disease. Parkinsonism and Related Dis 5: S90.
24. Hutchinson M, Fazzini E. 1996. Cholinesterase inhibition in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 61: 324-325.
25. Jellinger KA. 1999. Neuropathological correlates of mental dysfunction in Parkinson's disease: An update. In Mental Dysfunction in Parkinson's Disease, Wolters EC, Scheltens PH, Berendse HW (eds). Academic Pharmaceutical Productions BV: Utrecht; 82-105.
26. Jellinger KA, Bancher CH, Fischer P. 1994. Neuropathological correlates of mental dysfunction in Parkinson's disease. In Mental Dysfunction in Parkinson's Disease, Wolters EC, Scheltens PH (eds). ICG Printing: Dordrecht; 141-161.
27. Lezak MD. 1995. Neuropsychological Assessment. Oxford University Press: New York.
28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 76: 1-100.
29. Mattis S. 1988. Dementia Rating Scale (DRS) Professional Manual. Psychological Assessment Resources, Inc.: Odessa, FL.
30. Mayeux R, Denaro J, Hemenegildo N, et al. 1992. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 49: 492-497.
31. Mayeux R, Stern Y, Rosenstein R, et al. 1988. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 45: 260-262.
32. Nakano I, Hirano A. 1984. Parkinson's disease: Neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 15: 415-18.
33. Naville F. 1922. Etude sur les complications et les sequelles mentales de l'encephalite epidemique: La bradyphrenie. Encephale 17: 369-436.
34. Nelson HE. 1982. National Adult Reading Test (NART). Nelson Publishing Company: Windsor.
35. Ott BR, Lannon MC. 1992. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 15: 322-325.
36. Perry E, Walker M, Grace J, Perry R. 1999. Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 22: 273-280.
37. Perry E, Irving D, Kerwin JM, et al. 1993. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69-79.
38. Pirozzolo FJ, Hansch EC, Mortimer JC, Webster DD, Kuskowski MA. 1982. Dementia in Parkinson disease: A neuropsychological analysis. Brain Cogn 1: 71-83.
39. Reading PJ, Luce AK, McKeith IG. 2001. Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 16: 1171-1195.
40. Rogers SL, Farlow MR, Doody RS, et al. 1998. A 24-week, double-blind, placebo-controlled study of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145.
41. Ross GW, Mahler ME, Cummings JL. 1992. The dementia syndromes of Parkinson's disease: Cortical and subcortical features. In Parkinson's Disease, Neurobehavioral Aspects, Huber SJ, Cummings JL (eds). Oxford University Press: New York; 132-147.
42. Scheltens PH. 1999. Dementia in Parkinson's disease: Subclinical Alzheimer's disease. In Mental Dysfunction in Parkinson's Disease II, Wolters EC, Scheltens PH, Berendse HW (eds). Academic Pharmaceutical Productions: Utrecht; 189-193.
43. Schretlen D. 1997. Brief Test of Attention Professional Manual. Psychological Assessment Resources, Inc.: Odessa, FL.
44. Starkstein SE, Bolduc PL, Mayberg HS, et al. 1990. Cognitive impairments and depression in Parkinson's disease: A follow-up study. J Neurol Neurosurg Psychiatry 53: 597-602.
45. Sudarsky L, Morris J, Romero J, Walshe TM. 1989. Dementia in Parkinson's disease: The problem of clinicopathological correlation. J Neuropsychiatry Clin Neuroscience 1: 159-166.
46. Tiraboschi P, Hansen LA, Alford M, et al. 2000. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411.
47. Werber EA, Rabey JM. 2001. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108: 1319-1325.